Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.74 |
| ▸ | MAPK13 | O15264 | 9/20 | 0.71 |
| ▸ | MAPK12 | P53778 | 9/20 | 0.71 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.71 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.62 |
| ▸ | SRC | P12931 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3294796 | 0.91 | MAPK14 (0.75) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL5171341 | 0.90 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL4051549 | 0.89 | MAPK14 (0.69) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL4412697 | 0.87 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3293597 | 0.86 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3295412 | 0.86 | MAPK14 (0.83) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3183778 | 0.85 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3296791 | 0.85 | MAPK14 (0.77) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL2082569 | 0.84 | MAPK14 (0.80) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL27640941 | 0.84 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC | 2009-12-17 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
| US-20070191336-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312349-A1 | ANTI-INFLAMMATORY MEDICAMENTS | ABL2, ABL1, PTK2 | MAPK14 80/4885MAPK13 183/4885MAPK12 118/4885 |
| US-20070191336-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | MAPK14 29/4885MAPK13 41/4885MAPK12 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.